Summary
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), synthesized in this laboratory and currently in phase I clinical trial, is a low molecular weight inducer of tumour necrosis factor-α (TNF-α). Administration of DMXAA to mice with established transplantable tumours elicits rapid vascular collapse selectively in the tumour, followed by extensive haemorrhagic necrosis mediated primarily through the production of TNF-α. In this report we have investigated the synthesis of TNF-α mRNA in hepatic, splenic and tumour tissue. Co-administration of thalidomide with DMXAA increased anti-tumour activity and increased intra-tumoural TNF-α production approximately tenfold over that obtained with DMXAA alone. Thalidomide increased splenic TNF-α production slightly but significantly decreased serum and hepatic levels of TNF-α induced with DMXAA. Lipopolysaccharide (LPS) induced 300-fold higher serum TNF-α than did DMXAA at the maximum tolerated dose, but induced similar amounts of TNF-α in spleen, liver and tumour. Splenic TNF-α activity induced with LPS was slightly increased with thalidomide, but serum and liver TNF-α levels were suppressed. Thalidomide did not increase intra-tumoural TNF-α production induced with LPS, in sharp contrast to that obtained with DMXAA. While thalidomide improved the anti-tumour response to DMXAA, it had no effect on the anti-tumour action of LPS that did not induce a significant growth delay or cures against the Colon 38 tumour. The increase in the anti-tumour action by thalidomide in combination with DMXAA corresponded to an increase in intra-tumoural TNF-α production. Co-administration of thalidomide may represent a novel approach to improving selective intra-tumoural TNF-α production and anti-tumour efficacy of DMXAA.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Browne, W. L., Wilson, W. R., Rutland, M., Baguley, B. C. & Ching, L-M (1998). Suppression of serum tumour necrosis factor-α by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 18: 4409–4414.
Burroughs, M. H., Tsenova-Berkova, L., Sokol, K., Ossig, J., Tuomanen, E. & Kaplan, G. (1995). Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microb Pathogen 19: 245–255.
Carlesimo, M., Giustini, S., Rossi, A., Bonaccorsi, P. & Calvieri, S. (1995). Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866–869.
Casini, G. & Ferappi, M. (1964). Preparation of one optical antipode of 2-phthalimidoglutarimide. Farmaco 19: 563–565.
Ching, L. M., Joseph, W. R., Zhuang, L., Atwell, G. J., Rewcastle, G. R., Denny, W. A. & Baguley, B. C. (1991). Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with anti-tumour activity. Eur J Cancer 27: 79–83.
Ching, L. M., Joseph, W. R. & Baguley, B. C. (1992). Anti-tumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128–130.
Ching, L. M., Joseph, W. R., Crosier, K. E. & Baguley, B. C. (1994a). Induction of tumour necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870–872.
Ching, L. M., Joseph, W. R., Zhuang, L. & Baguley, B. C. (1994b). Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of Colon 38 tumours. Cancer Chemother Pharmacol 35: 153–160.
Ching, L. M., Xu, Z-F, Gummer, B. H., Palmer, B. D., Joseph, W. R. & Baguley, B. C. (1995). Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72: 339–343.
Ching, L. M., Browne, W. L., Tchernegovski, R., Gregory, T., Baguley, B. C. & Palmer, B. D. (1998). Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity. Br J Cancer 78: 336–343.
D’Amato, R. J., Loughnan, M. S., Flynn, E. & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085.
Fabro, S., Smith, R. L. & Williams, R. T. (1967). Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215: 296
Gardner-Medwin, J. M., Smith, N. J. & Powell, R. J. (1994). Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53: 828–832.
Gutierrez-Rodriguez, O., Starusta-Bacal, P. & Gutierrez-Montes, O. (1989). Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 16: 158–163.
Han, J., Thompson, P. & Beutler, B. (1990). Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391–394.
Haslett, P. A. J., Corral, L. G., Albert, M. & Kaplan, G. (1998). Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the cd8+ subset. J Exp Med 187: 1885–1892.
Hogan, M. M. & Vogel, S. N. (1990). Measurement of tumor necrosis factor alpha and beta. In Current Protocols in Immunology, Vol. 1, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (eds), p. 6.10.1. Greene Publishing Associates and Wiley Interscience: New York
Joseph, W. R., Cao, Z., Mountjoy, K. G., Marshall, E. S., Baguley, B. C. & Ching, L. M. (1999). Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633–638.
Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J. & Wilson, W. R. (1998). Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanethenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439–445.
Mahadevan, V., Malik, S. T. A., Meager, A., Fiers, W., Lewis, G. P. & Hart, I. R. (1990). Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537–5542.
Makonkawkeyoon, S., Limson-Pobre, R. N. R., Moreira, A. L., Schauf, V. & Kaplan, G. (1993). Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90: 5974–5978.
Miyachi, H., Azuma, A., Hioki, E., Iwasaki, S., Kobayashi, Y. & Hashimoto, Y. (1996). Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 224: 426–430.
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A. & Kaplan, G. (1993). Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675–1680.
Moreira, A. L., Corral, L. G., Ye, W., Johnson, B., Stirling, D., Muller, G. W., Freedman, V. H. & Kaplan, G. (1997). Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13: 857–863.
Patel, S., Parkin, S. M. & Bibby, M. C. (1997). The effect of 5,6-dimethylxanthenone- 4-acetic acid on tumor necrosis factor production by human immune cells. Anticancer Res 17: 141–150.
Philpott, M., Baguley, B. C. & Ching, L-M (1995). Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143–148.
Philpott, M., Joseph, W. R., Crosier, K. E., Baguley, B. C. & Ching, L. M. (1997). Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76: 1586–1591.
Pratesi, G., Rodolfo, M., Rovetta, G. & Parmiani, G. (1990). Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079–1083.
Rewcastle, G. W., Atwell, G. J., Zhuang, L., Baguley, B. C. & Denny, W. A. (1991). Potential antitumor agents. 61. Structure–activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217–222.
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A. & Kaplan, G. (1991). Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med 173: 699–703.
Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A. & Jongeneel, C. V. (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171: 35–47.
Shannon, E. J. & Sandoval, F. (1996). Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 18: 59–72.
Shannon, E. J., Howe, R. C., McLean, K. & Hastings, R. C. (1994). Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential. Immunopharmacol Immunotoxicol 16: 717–729.
Sheskin, J. (1965). Further observation with thalidomide in lepra reactions. Leprosy Rev 36: 183–187.
Silva, S. R. B., Viana, P. C. F., Lugon, N. V., Hoette, M., Ruzany, F. & Lugon, J. R. (1994). Thalidomide for the treatment of uremic pruritus: a crossover randomised double-blind trial. Life Sci 31: 270–273.
Teicher, B. A., Sotomayor, E. A. & Huang, Z. D. (1992). Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702–6704.
Turk, B. E., Jiang, H. & Liu, J. O. (1996). Binding of thalidomide to alpha(1)-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552–7556.
Uthoff, K., Zehr, K. J., Gaudin, P. B., Kumar, P., Cho, P. W., Vogelsang, G., Hruban, R. H., Baumgartner, W. A. & Stuart, R. S. (1995). Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 59: 277–282.
Vogelsang, G. B., Santos, G. W., Colvin, O. M. & Chen, T. (1988). Thalidomide for graft-versus-host disease. Lancet 1: 827
Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamonte, V., Beschorner, W. E., Jabs, D. A., Corio, R. L., Levin, L. S., Colvin, O. M., Wingard, J. R. & Santos, G. W. (1992). Thalidomide for the treatment of chronic graft-versus-host disease. New England J Med 326: 1055–1058.
Yang, D., Satoh, M., Ueda, H., Tsukagoshi, S. & Yamazaki, M. (1994). Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38: 287–293.
Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. (1994). Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79–85.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cao, Z., Joseph, W., Browne, W. et al. Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80, 716–723 (1999). https://doi.org/10.1038/sj.bjc.6690415
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690415
Keywords
This article is cited by
-
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
Cancer Chemotherapy and Pharmacology (2014)
-
Plant-derived vascular disrupting agents: compounds, actions, and clinical trials
Phytochemistry Reviews (2014)
-
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
British Journal of Cancer (2013)
-
Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn
Cancer Chemotherapy and Pharmacology (2009)
-
Vascular targeting agents
Current Oncology Reports (2004)